We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current ACHL market cap is 0. The company's latest EPS is USD and P/E is N/A.
Quarter End | Mar 2023 | |||
---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 1.09M | |||
Operating Income | -17.46M | |||
Net Income | -17.51M |
Year End 31 December 2022 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 531k | 3.13M | 7.32M |
Operating Income | -13.76M | -33.2M | -61.06M | -71.13M |
Net Income | -13.99M | -33.2M | -61.1M | -71.18M |
Quarter End | Mar 2023 | |||
---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 207.64M | |||
Total Liabilities | 22.46M | |||
Total Equity | 185.17M |
Year End 31 December 2022 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 105.21M | 218.92M | 317.11M | 220.36M |
Total Liabilities | 3.86M | 29.55M | 27.58M | 23.31M |
Total Equity | 101.35M | 189.37M | 289.53M | 197.04M |
Quarter End | Mar 2023 | |||
---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | N/A | |||
Investing | N/A | |||
Financing | N/A |
Year End 31 December 2022 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -14.14M | -25.25M | -59.28M | -59.54M |
Investing | -942k | -11.85M | -7.63M | -7.51M |
Financing | 93.62M | 113.7M | 160.76M | 1,000 |
Market Cap | 0 |
Price to Earnings Ratio | N/A |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 0 |
Price to Book Ratio | 0 |
Dividend Yield | - |
Shares Outstanding | 0 |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 0.03 (3.54%) |
Company Name | Achilles Therapeutics PLC |
Address |
245 hammersmith road london W6 8PW |
Website | https://www.achillestx.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions